A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

DRUG: SRT2104

Sponsor

Sirtris, a GSK Company

Collaborators

[object Object]